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The spread of HIV-1 over time has occurred 
mainly through sexual transmission. This trans-
mission necessitates that minute amounts of 
virus traverse mucosal surfaces to reach replica-
tion-competent sites in lymphoid tissue. Model 
systems have indicated that one of the key 
events during this transmission is the transfer of 
HIV infection from DCs to CD4+ T cells (for 
review see references 1–3).
HIV infects DCs in vitro only when rela-
tively high viral inocula are used (for review see 
reference 1) (4–6). Presently, the mechanism re-
sponsible for the poor replication of HIV in im-
mature DCs (iDCs), the type of DCs that likely 
encounters HIV in the mucosal tissues during 
sexual transmission, has not been elucidated.
In the absence of viral replication, DCs also 
can capture and transfer viral material to CD4+ 
T cells via an infectious synapse, which results 
in vigorous infection (7–10). The contribution 
of this “capture–transfer” pathway remains un-
clear in vivo.
Langerhans cells/DCs replicate at low lev-
els, preferentially HIV-1 R5 compared with 
HIV-1 X4 (5, 11, 12). This preferential repli-
cation of R5 strains versus X4 strains appears to 
be caused in part by levels of coreceptors on 
the surface of iDCs and is also partly due to a 
block during viral fusion with iDCs (11, 12). 
However, infection of iDCs is still ineffi   cient, 
irrespective of the viral env, when compared 
with activated CD4+ T cells (for review see 
reference 1).
In this study, we asked whether iDCs ex-
pressed an env-independent intrinsic resistance 
to HIV-1 infection that could operate after 
viral entry. The idea of intrinsic resistance 
derives from the discovery of cellular restric-
tion factors to HIV-1 infection (for review see 
reference 13). Two families of restriction fac-
tors in human cells have been recently identi-
fi  ed: the TRIM family and the APOBEC family 
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(14, 15). Specifi  cally, one member of each family can oper-
ate, at least in some circumstances, after viral entry and before 
viral integration into the nucleus (e.g., TRIM5α [T5α] and 
APOBEC3G [A3G]) (15, 16). Human T5α restricts HIV-1 
only weakly (15), whereas A3G eff  ectively restricts HIV-1 
after entry in primary cells such as resting CD4+ T cells (16). 
In fact, A3G is a potent host antiretroviral factor that can re-
strict HIV-1 infection through at least two mechanisms. First, 
A3G is a DNA deaminase that is incorporated into virions 
during viral production and subsequently triggers massive 
G-to-A hypermutation in the nascent retroviral DNA (17, 18). 
This mode of action is counteracted by Vif that prevents in-
corporation of A3G into virions (19). Second, cellular A3G 
can function as a post-entry restriction factor for HIV during 
reverse transcription in resting CD4+ T cells (16), where it 
resides in a low molecular mass (LMM) active form. This 
second mechanism does not seem to be counteracted by Vif, 
because incoming viral particles contain little Vif. The poten-
tial contribution of these cellular restriction factors to the 
low levels of HIV-1 infection in iDCs has not been tested. In 
this paper, we demonstrate an env-independent restriction to 
HIV-1 infection in human iDCs using single-round infection 
assays with viral particles pseudotyped with vesicular stomati-
tis virus G (VSVG). We will demonstrate a role for A3G, and 
to a lesser extent for APOBEC3F (A3F), in restriction of 
HIV-1 infection in DCs.
RESULTS
HIV-1 replication is restricted in iDCs
We generated iDCs after 6 d of culture of monocytes in GM-
CSF and IL-4, as previously described, and verifi  ed that the 
iDCs expressed the expected markers (i.e., CD14− and MHC 
class II+) (9, 20). To overcome the entry block that has been 
described in iDCs, we used single-round infection assays with 
HIV-1 ∆ env and pseudotyped with VSVG (HIV-VSVG; 
Fig. 1 A). Similar results were obtained using a lentiviral vector 
(LV) that is deleted in env, vif, vpr, vpu, and nef (LV-VSVG), 
indicating that the low susceptibility of iDCs to HIV infec-
tion was independent of these virulence genes (Fig. 1 B). 
iDCs were at least 50–100 times less susceptible to HIV-
VSVG infection than Jurkat CD4+ T cells (JTs; Fig. 1, A–C). 
HIV-VSVG infection was equally effi   cient in activated pe-
ripheral blood lymphocytes and in JTs (unpublished data).
A3G/3F, but not T5𝗂, are active restriction factors in iDCs
To explore whether a cellular restriction factor operates in 
iDCs, we used RNA interference to target the cellular re-
striction factors, members of the APOBEC family (A3G and 
A3F), as well as T5α. Monocyte-derived DCs (mDCs) were 
transfected with small interfering RNA (siRNA) sequences 
specifi  c for the target gene using lipofectamine reagent. The 
extent of down-regulation was monitored by Western blot-
ting followed by densitometry analysis. Double transfection 
of a mix of three siRNA targeting A3G induced an effi   -
cient knockdown in 293T cells stably expressing A3G-HA 
(293T-A3G-HA cells; 80% down-regulation; Fig. 2 A) or 
in iDC (60–80% down-regulation; Fig. 2 B), which is an 
effi   ciency comparable to that reported for RNA interfer-
ence of A3G in resting CD4 T cells (16). In 293T-A3G-
HA cells, siRNA-mediated interference of A3G did not 
increase HIV-1 infection (Fig. 2 C), but HIV infection was 
enhanced >7-fold (range = 2–22-fold, depending on the 
donor) in A3G knockdowned iDCs in comparison with 
control cells treated with equal amounts of siRNA targeting 
an irrelevant sequence (Fig. 2 D). Based on these results, we 
conclude that HIV-1 infection in iDCs is restricted at least 
in part by A3G.
A second APOBEC family member, A3F, also possesses 
antiviral function, though it is 10–100-fold less than potent 
than A3G (21, 22). We targeted A3F with a combination of 
two siRNA in iDCs, which induced an effi   cient knockdown 
of this protein in 293T cells transiently expressing A3F-HA 
(unpublished data). A3F knockdown in iDCs increased HIV 
infection approximately threefold (i.e., less effi   ciently than 
A3G knockdown [approximately sevenfold]; Fig. 2 D). Dou-
ble knockdown experiments (A3G+A3F) were not feasible, 
possibly because of the large amounts of siRNA used to 
knockdown both genes (unpublished data).
Figure 1.  HIV-1 infection is restricted in iDCs. (A) Infection of 
iDCs and JTs with full-length HIV-1 vector encoding GFP and pseudo-
typed with VSVG (HIV-VSVG; MOI = 1). GFP expression was followed 
by FACS after 3 d of infection. One representative experiment out of 
two is shown. (B) iDCs and JTs were infected with a multiply deleted LV 
encoding GFP pseudotyped with VSVG (LV-VSVG; MOI = 1). One repre-
sentative experiment out of two is shown. Boxes in A and B indicate 
that GFP+ cells are in that gate. (C) Infection of iDCs or Jurkat cells 
with increasing amounts of LV-VSVG (open symbols) or HIV-VSVG 
(closed symbols; MOI = 0.01–10). One representative experiment out 
of two is shown. ■ and □, GFP expression in JTs; ▲ and △, GFP ex-
pression in iDCs.JEM VOL. 203, December 25, 2006  2889
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To substantiate the involvement of A3G/3F proteins in the 
early block observed in DCs, we analyzed the sequences of viral 
reverse transcripts 8 h after infection (Fig. 2 E). A substantial 
fraction of the incoming viral DNA molecules ( 17%) har-
bored G-to-A mutations, the hallmark of an A3G/3F action.
Because T5α is another factor that can restrict HIV-1 in-
fection in several cell types (15, 23), we used RNA interfer-
ence to knock down human T5α in HeLa stably overexpressing 
T5α-HA (HeLa-T5α-HA;  80% down-regulation of T5α; 
Fig. 3, A and B, left) and in iDCs ( 80% down-regulation of 
T5α; Fig. 3, A and B, right). Although RNA interference of 
T5α in HeLa-T5α-HA relieved the block imposed to mu-
rine leukemia virus–N in human cells as expected (Fig. 3, C 
and D, left), interference of endogenous human T5α in iDCs 
did not increase HIV-VSVG infection (Fig. 3, C and D, 
right). Thus, human T5α is not a potent cellular restriction 
factor to HIV infection in iDCs.
A3G messenger RNA (mRNA) is absent in permissive iDCs
In spite of the ineffi   ciency of infection of iDCs, a small frac-
tion of the cells do support productive infection (24). To 
pursue the basis for the permissiveness of a subset of iDCs, we 
Figure 2.  A3G restricts HIV-1 infection in iDC 293T. A3G-HA cells (A) 
or iDCs (B) were transfected with siRNA against A3G (Si-A3G) or siRNA 
control (Si-Ctrl). After two rounds of transfection, cells were analyzed by 
Western blot (A and B, left). The percentage of protein expression on Western 
blot was quantifi  ed by density of specifi  c bands and normalized with Si-Ctrl 
(A and B, right). 293T-A3G-HA cells (C) or iDCs (D) transfected by Si-A3G 
and Si-Ctrl were infected with HIV-VSVG. GFP expression was followed by 
FACS (numbers are the percentage of GFP+ cells; C and D, left), and the fold 
enhancement of GFP expression was calculated by normalization with non-
treated (NT) cells (C and D, right). A pool of fi  ve independent experiments is 
shown for A3G (±SEM), and two independent experiments are shown for 
A3F (±SEM). NI, noninfected. (E) A3G/3F induce G-to-A hypermutation of 
HIV genomes during iDC infection. Sequences represent individual HIV-1 
reverse transcripts obtained after an 8-h infection of iDCs and are repre-
sentative of the 7 hypermutated sequences (17%) that were obtained 
among 40 reverse transcripts. The standard HIV NL4.3 numbering is used.2890  HIV RESTRICTION IN HUMAN DENDRITIC CELLS | Pion et al.
infected iDCs with HIV-VSVG, and 5 d later, GFP+ and 
GFP− cells were sorted by FACS (Fig. 4 A). We performed 
RT-PCR for A3G/A3F and T5α on GFP+ and GFP− cells. 
Strikingly, A3G mRNA was severely decreased in GFP+ 
permissive iDCs in comparison with GFP− iDCs, whereas 
A3F and T5α mRNA were equally present in both fractions 
of iDCs (Fig. 4 B). Tubulin was used as a loading control, in-
dicating that this result was not explained by diff  erences in 
cell counts between the GFP+ and GFP− populations. We 
also performed a Western blot analysis. A3G protein levels 
were decreased in the GFP+ iDCs in comparison with GFP− 
iDCs (Fig. 4 C). Because HIV Vif does not aff  ect  A3G 
mRNA in infected cells (19), this result suggests that the sus-
ceptibility of a fraction of iDCs to HIV-1 is caused by the ab-
sence of A3G mRNA before infection of these cells.
DC maturation positively modulates A3G expression levels
To analyze whether DC maturation modulates A3G activity, 
we activated iDCs with maturing agents such as LPS. LPS 
triggered the up-regulation of CD83, HLA-DR, CD80, and 
CD86 by FACS (unpublished data). In contrast to the acti-
vation of resting CD4+ T cells, which increases HIV-1 infec-
tion, LPS-induced maturation of DCs further decreased 
infection of HIV-VSVG relative to iDCs  5–10-fold (Fig. 5 A). 
We next quantifi  ed A3G expression by Western blot analysis 
in iDCs and mDCs. mDCs expressed three to fi  vefold more 
A3G than iDCs (Fig. 5 B). A3F antibodies did not function 
for Western blot analysis, thus precluding this type of analysis 
for A3F in mDCs (unpublished data). RNA interference of 
A3G in mDCs was ineffi   cient, perhaps because of the low 
capacity of mDCs for internalization, which prevented us 
from directly testing the capacity of A3G to control HIV-1 
infection in mDCs. Nevertheless, these results suggest that 
DC maturation further restricts HIV-1 infection through an 
increase in A3G expression.
To evaluate whether A3G was present in an LMM active 
form in DCs as previously observed in resting CD4+ T cells 
(16), we designed an assay where we separated cytosolic pro-
teins from a pellet (P) fraction (containing heavy membranes, 
endosomes, and nucleus) by high speed centrifugation. We 
reasoned that because A3G LMM was most likely in a cyto-
solic unbound form, we could extract cytosolic A3G in a su-
pernatant (SN) fraction (A3G SN) and leave other higher 
molecular forms of A3G in the P fraction. Using this assay, 
we found that A3G was exclusively in the P in cells highly 
sensitive to HIV infection, such as 293T and H9 CD4+ T 
cells, and no A3G SN was detected (Fig. 5 C). We next ana-
lyzed A3G distribution in primary cells and identifi  ed a strong 
proportion of A3G SN in cells restrictive to HIV infection, 
such as monocytes and resting CD4+ T cells, but not in acti-
vated CD4+ T cells, where A3G SN levels were low (Fig. 
5 C). These controls are consistent with the fact that our 
simplifi  ed assay can determine the proportion of A3G LMM 
described in (16), which only identifi  ed A3G SN in cells 
  restrictive to HIV infection (similar to the A3G LMM) and 
does not provide specifi  c information on the high molecular 
mass forms of A3G. When we subjected iDCs and mDCs 
to the same analysis, A3G SN was present in iDCs but 
Figure 3.  Human T5𝗂 does not restrict HIV-1 infection in iDCs. 
HeLa-T5α-HA cells (A and B, left) or iDCs (A and B, right) were transfected 
with siRNA against T5α (Si-T5α) or siRNA control (Si-Ctrl). After two 
rounds of transfection, the cells were lysed and analyzed by Western blot (A). 
The percentage of protein expression on Western blot was quantifi  ed 
by the density of specifi  c bands and normalized with Si-Ctrl (B). HeLa-
T5α-HA (C and D, left) or iDC (C and D, right) knockdowns for T5α were 
infected with MLV-GFP or HIV-VSVG. GFP expression was followed by 
FACS (C), and the fold enhancement of GFP expression was calculated by 
normalization with cells treated with Si-Ctrl. Boxes indicate the percent-
age of GFP+ cells. (D). Results are a pool of three independent experiments 
(±SD). MLV, murine leukemia virus.JEM VOL. 203, December 25, 2006  2891
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was strongly up-regulated in mDCs (Fig. 5 C). In all these 
cells, the proportion of A3G SN correlated with the HIV 
  restriction phenotype (Fig. 5 D); i.e., mDCs showed a high 
level of A3G SN, in accordance with their low susceptibility 
to HIV, whereas iDCs had an intermediate level of A3G 
SN and an intermediate resistance to HIV infection (Fig. 
5, A and D).
D  I  S  C  U  S  S  I  O  N 
We have investigated two features in the infection of iDCs, 
the cells that are implicated in transmission of HIV to T cells: 
fi  rst, the poor susceptibility of iDCs relative to activated T 
cells, and second, the permissiveness of a small subset of iDCs 
to replication of HIV-1. Although the resistance of DCs to 
HIV-1 has been known (for review see references 1, 2), the 
underlying mechanisms have remained unclear. Envelope-
dependent blocks during entry explain the fact that CXCR4low 
CCR5+ iDCs are poorly infectable by HIV-1 X4 and allow 
entry of R5 virus (5, 25). We and others also have described 
a block during viral fusion for HIV-1 X4 with iDCs (9, 11) 
independent of CXCR4 levels (12). However, even when 
HIV is pseudotyped with VSVG, iDCs are less infectable 
than JTs or activated PBLs, indicating that a cellular restric-
tion also operates post-entry in iDCs.
We therefore considered the two families of restriction 
factors (TRIM/APOBEC) that have been identifi  ed in hu-
man cells (for review see reference 13). Among their family 
members, T5α and A3G are known to block HIV-1 after vi-
ral entry in select cells. T5α did not operate as a strong re-
striction factor in iDCs. This is not surprising given the fact 
that human T5α restricts HIV-1 only weakly in human cells 
(15). On the other hand, human A3G does function as a po-
tent post-entry cellular restriction factor for HIV-1 in resting 
CD4+ T cells (16). A3G acts through cytidine deaminase ac-
tivity (17, 18), as well as through less well-understood non-
enzymatic mechanisms (26).
Three separate lines of evidence indicated that A3G could 
restrict HIV-1 infection in iDC. First, RNA interference of 
A3G in iDCs considerably increased HIV-1 infection in these 
cells. Interestingly A3F down-regulation also enhanced HIV 
infection in iDCs, though to a lesser extent than A3G down-
regulation, suggesting that both A3G/3F may contribute to 
restricting HIV infection in iDCs. To confi  rm the involve-
ment of A3G/3F in the early block of HIV infection in DCs, 
we analyzed the sequences of viral reverse transcripts. A sub-
stantial fraction of the incoming viral DNA molecules (17%) 
harbored G-to-A mutations, the hallmark of an active cyti-
dine deaminase like A3G/3F, and these hypermutations har-
bored the signatures of both A3F and A3G action. Based on 
the known respective frequencies of their diff  erent signatures 
(21), it can be deduced that both enzymes contribute compa-
rably to the total mutations found in reverse transcripts. It 
appears, however, that A3G is probably the main contributor 
to the restriction, because its RNA interference–mediated 
ablation leads to the strongest relief of the block in iDCs.
Second, iDC that were infectable with HIV-VSVG did 
not express A3G mRNA or A3G protein. Therefore, our re-
sult indicates that low A3G mRNA in a subset of iDCs possi-
bly increases permissivity to HIV-1. Interestingly, A3F was 
expressed in both infected and uninfected iDC populations, 
which correlates with its less important contribution to the 
restriction of HIV infection in iDCs, as determined by RNA 
interference studies.
Third, we tried to modulate A3G expression and func-
tion in DCs by inducing DC maturation. Unlike resting 
CD4+ T cells that become permissive upon activation 
(16), DCs are more restrictive after maturation/activation. 
Interestingly A3G levels were up-regulated in mDCs, fur-
ther indicating a link between A3G and HIV-1 infection 
in iDCs.
The recent description of A3G in an enzymatically active 
LMM form in resting CD4+ T cells and monocytes (16, 27) 
suggests that A3G possibly exists in that active LMM form in 
DCs as well. We recapitulated a simplifi  ed version of the as-
say in which we separated A3G SN that behaved similarly to 
A3G LMM. Our results demonstrated that the presence of 
A3G SN correlated with restriction. Monocytes and resting 
CD4+ T cells had the highest quantity of SN A3G and were 
Figure 4.  HIV-VSVG infects iDCs that express low levels of A3G. 
(A) iDCs were infected with HIV-VSVG and sorted after 5 d as GFP+ 
  (infected) and GFP− (noninfected) fractions. (B) RNA was extracted and 
subjected to RT-PCR for A3G (30 cycles), A3F (35 cycles), T5α (35 cycles), 
and tubulin. (C) Proteins extracted from the same cells were used in Western 
blot for A3G and tubulin. The fi  gure shows two different cell preparations. 
NI, uninfected control cells.2892  HIV RESTRICTION IN HUMAN DENDRITIC CELLS | Pion et al.
not infectable. 293T and activated CD4+ T cells had low 
amounts of A3G SN and were completely permissive. Inter-
estingly, mDCs had more A3G SN than iDCs. Collectively, 
our results indicate that A3G restriction explains, at least in 
part, the post-entry block observed in iDCs. Attempts to 
modulate A3G/A3F function in DCs could off  er the poten-
tial to counteract HIV infection before its dissemination dur-
ing the early events of HIV-1 transmission.
MATERIALS AND METHODS
Virus stocks. These were produced by transient transfection of 293T cells. 
Infection assays were performed as previously described (9, 20). Details about 
the viral constructs used are in Supplemental materials and methods, avail-
able at http://www.jem.org/cgi/content/full/jem.20061519/DC1.
Preparation of primary mDCs. Monocyte isolation from buff  y coats of 
healthy donors (obtained according to guidelines of the ethical committees 
of the University of Geneva and the Rockefeller University) and subsequent 
generation of iDCs was performed as previously described (20). DC matura-
tion was induced by 48 h of LPS stimulation at 20 ng/ml (Escherichia coli, 
strain 055:B5; Difco).
Cell culture reagents. HeLa-T5α-HA cells and 293T-A3G cells (a gift of 
D. Trono, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland) 
were grown and maintained in DMEM with 10% FCS, 100 μg/ml   penicillin 
and streptomycin, and 2 mM glutamine.
RNA interference in iDCs. mDCs were transfected with siRNA se-
quences specifi  c for the target gene using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s recommendations, with modifications 
available in Supplemental materials and methods.
Sequencing of viral DNA. iDCs were infected with DNase-treated HIV-
VSVG-GFP virions at a multiplicity of infection (MOI) of 10. Viral reverse 
  transcripts were extracted with the DNeasy kit (QIAGEN) 8 h after infection and 
individually amplifi  ed by standard PCR using O.nef1 and O.U5.1 primers (see 
Supplemental materials and methods). They were then cloned with a cloning kit 
(TOPO-TA; Invitrogen) and sequenced. Finally, Clone Manager software 
  (version 8; Scientifi  c & Educational Software) was used for the alignments.
RT-PCR from iDC-infected cells. iDCs were infected with HIV-VSVG 
expressing GFP (2 ng p24 gag/105 cells) for 5 d. Cells were sorted as GFP+ 
(infected) or GFP− (noninfected). Total RNA was extracted with TRIzol 
(Invitrogen). RT-PCR was performed with 0.5 μg RNA using SuperScript 
one-step RT-PCR (Invitrogen). PCR for A3G and T5α was performed by 
30 cycles of amplifi  cation at 94°C for 15 s, 55°C for 30 s, and 72°C for 
1 min, or at 94°C for 15 s, 48°C for 30 s, and 72°C for 1 min, respectively, 
with gene-specifi  c primers (see Supplemental materials and methods).
A3G subcellular localization. Cells (see Supplemental materials and 
methods) were lysed with ice-cold lysis buff  er (125 mM NaCl, 50 mM 
Hepes, pH 7.4, 0.2% NP40, 1 mM dithiothreitol, 0.1 mM PMSF, EDTA-
free protease inhibitor cocktail; Sigma-Aldrich) for 30 min and centrifuged 
at 35,000 rpm (MC M150GX; Sorvall) for 1.5 h. SN and P were separated, 
Figure 5.  DC maturation increases A3G levels and further restricts 
HIV-1 infection. (A) Infection of iDCs and mDCs with HIV-VSVG. DCs 
were infected with increasing amounts of HIV-VSVG. GFP expression was 
followed by FACS after 3 d of infection. One representative experiment 
out of two is shown. (B) Analysis of A3G expression in iDCs, mDCs, 293T-
A3G-HA cells, and HeLa cells by Western blot. (C) DCs contain A3G in the 
SN fraction (A3G SN). Control cells (top) and primary cells (bottom) were 
lysed and centrifuged at high speed. Equal volumes of P and SN fractions 
were analyzed by Western blotting. Numbers represent the amount of 
A3G in SN and P; A3G expression in SN was quantifi  ed, with a value of 1 
assigned to the P. One representative experiment out of three is shown. 
(D) A3G SN correlates with restriction to HIV infection in DCs. Single-
round infection experiments were performed with a VSVG-pseudotyped 
HIV-GFP virus. GFP+ cells were evaluated by FACS 3 d after infection. 
Infectivity of the different cell types is represented: high (+++), >75%; 
moderate (++), 40–50%; low, (+/−) <10–15%; very low (+/−−), 
<5%; none (−); and not determined (ND). One representative experiment 
out of three is shown (±SD).JEM VOL. 203, December 25, 2006  2893
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and P was resuspended in a volume equal to that of SN and sonicated for 
20 s (Sonic B12; Branson). Equal volumes of P and SN were loaded on gel 
and analyzed by standard Western blotting. Protein expression was quanti-
fi  ed by densitometry analysis of specifi  c bands. Ratios of A3G SN were cal-
culated as a ratio of A3G SN/P, where the A3G P fraction had an arbitrary 
value of 1 based on densitometry analysis.
Online supplemental material.  Supplemental materials and methods 
contains information about virus stocks, RNA interference in iDCs, siRNA 
and primer sequences, antibodies, and A3G subcellular localization. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20061519/DC1.
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